India's Jubilant Pharmova rises after USFDA nod for Spokane line
BUZZ-India's Jubilant Pharmova rises after USFDA nod for Spokane line ** Shares of Jubilant Pharmova JUBA.NS rise as much as 5.4%, last up 1% at 890 rupees
** The drugmaker's unit gets USFDA approval for its new isolator based fill and finish line, line three at contract manufacturing facility, Spokane, U.S.A
** Stock set to rise for a fourth straight session
** YTD, JUBA down ~18%
(Reporting by Anuran Sadhu in Bengaluru)
((Anuran.Sadhu@thomsonreuters.com; +91 8697274436;))
Recent news on Jubilant Pharmova
See all newsBrief: Jubilant Pharmova Sept-Quarter Consol Net Profit 312 Million Rupees
Brief: Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
India New Issue-Jubilant Pharmova to issue 3-year bonds, bankers say
India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
Brief: Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures